top_banner
Cancer News

Recent Acute Lymphoblastic Leukemia News
FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive... Continue Reading

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience... Continue Reading

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia (September 6, 2016)

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to... Continue Reading

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia (June 23, 2016)

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia... Continue Reading

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia (May 16, 2016)

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These... Continue Reading

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (January 19, 2016)

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic... Continue Reading

Next Page »